Research programme: EP2 receptor agonists - Argenta DiscoveryAlternative Names: Research programme: EP2 receptor agonist - Argenta Discovery
Latest Information Update: 21 Jul 2010
At a glance
- Originator Argenta Discovery
- Mechanism of Action Dinoprostone agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Bone disorders; Osteoporosis
Most Recent Events
- 15 Apr 2004 Preclinical trials in Bone disorders in United Kingdom (unspecified route)
- 15 Apr 2004 Compounds from this research programme are available for licensing (http://www.argentadiscovery.com)
- 15 Apr 2004 Preclinical trials in Osteoporosis in United Kingdom (unspecified route)